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Effects of stent generation 
on clinical outcomes after acute 
myocardial infarction compared 
between prediabetes and diabetes 
patients
Yong Hoon Kim 1,5*, Ae‑Young Her 1,5, Myung Ho Jeong 2, Byeong‑Keuk Kim 3, 
Sung‑Jin Hong 3, Seunghwan Kim 4, Chul‑Min Ahn 3, Jung‑Sun Kim 3, Young‑Guk Ko 3, 
Donghoon Choi 3, Myeong‑Ki Hong 3 & Yangsoo Jang 3
We investigated the effects of stent generation on 2‑year clinical outcomes between prediabetes 
and diabetes patients after acute myocardial infarction (AMI). A total of 13,895 AMI patients were 
classified into normoglycemia (group A: 3673), prediabetes (group B: 5205), and diabetes (group C: 
5017). Thereafter, all three groups were further divided into first‑generation (1G)‑drug‑eluting stent 
(DES) and second‑generation (2G)‑DES groups. Patient‑oriented composite outcomes (POCOs) 
defined as all‑cause death, recurrent myocardial infarction (Re‑MI), and any repeat revascularization 
were the primary outcome. Stent thrombosis (ST) was the secondary outcome. In both prediabetes 
and diabetes groups, the cumulative incidences of POCOs, any repeat revascularization, and ST were 
higher in the 1G‑DES than that in the 2G‑DES. In the diabetes group, all‑cause death and cardiac death 
rates were higher in the 1G‑DES than that in the 2G‑DES. In both stent generations, the cumulative 
incidence of POCOs was similar between the prediabetes and diabetes groups. However, in the 
2G‑DES group, the cumulative incidences of Re‑MI and all‑cause death or MI were significantly higher 
in the diabetes group than that in the prediabetes group. To conclude, 2G‑DES was more effective 
than 1G‑DES in reducing the primary and secondary outcomes for both prediabetes and diabetes 
groups.
Diabetes mellitus (DM, diabetes) is regarded as a “coronary artery disease (CAD) risk equivalent”1, conferring 
an approximately twofold increased risk of acute myocardial infarction (AMI)2. Moreover, almost two thirds 
of those presenting with CAD have either diabetes or  prediabetes2. Coronary vessels in patients with diabetes 
usually present extensive atherosclerosis with a larger number of significant stenosis, longer lesions, and more 
diffuse  disease3,4. Therefore, despite advances in interventional skill, devices, and antiplatelet agents, outcomes 
of coronary revascularization in patients with diabetes have been poorer than those  without5,6. Percutaneous 
coronary intervention (PCI) in patients with diabetes is associated with increased incidence of restenosis, repeat 
revascularization, stent thrombosis (ST), and all-cause mortality than those  without3,4. Drug-eluting stents (DES) 
reduce the risk of restenosis as compared with bare-metal stents (BMS). However, ST remains a major concern 
after the implantation of first-generation (1G)-DES in patients with  diabetes7. Relative superiority between the 
1G- and 2G-DESs in patients with diabetes remains  controversial8–11. Although recent reports revealed that 
prediabetes is an intergrade between normoglycemia and  diabetes12–14, PCI patients with prediabetes were prone 
to experience adverse clinical events. Individuals with prediabetes are important and common patients who visit 
interventional cardiologists. However, the main treatment strategies for hyperglycemia are focused on the patients 
with diabetes rather those with  prediabetes15. Moreover, studies regarding the effects of the 1G-DES and 2G-DES 
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on clinical outcomes between prediabetes and diabetes patients after AMI were limited. To better understand 
the characteristic of prediabetes, we compared the 2-year clinical outcomes of the 1G-DES and 2G-DES under 
two different glycemic states (prediabetes and diabetes).
Results
Baseline characteristics. Table 1 summarizes the baseline clinical, laboratory, and procedural characteris-
tics of the study population. The study population consisted of patients who had a relatively well-preserved left 
ventricular ejection fraction (LVEF; mean: 52.1 ± 11.4%). The mean value of high-sensitivity C-reactive protein 
(hs-CRP) and number of patients who received clopidogrel and cilostazole as the discharge medications were 
significantly higher in 1G-DES group than in 2G-DES group in all three different glycemic groups. In contrast, 
the number of patients requiring cardiopulmonary resuscitation (CPR) on admission; number of patients who 
received PCI within 24  h; number of patients who received aspirin, ticagrelor, prasugrel, beta-blockers, and 
lipid lowering agents as the discharge medications; American College of Cardiology/American Heart Associa-
tion (ACC/AHA) type C lesion; and mean length of deployed stent were significantly higher in 2G-DES group 
than in 1G-DES group in all three different glycemic groups. However, the mean value of age, LVEF, body mass 
index, systolic blood pressure; number of ST-segment-elevation myocardial infarction (STEMI) and dyslipi-
demia; number of patient with previous history of PCI, coronary artery bypass graft, cerebrovascular accident, 
and heart failure; number of current smoker and treated vessel; mean value of serum creatinine and diameter of 
deployed stent; and the use of intravascular ultrasound (IVUS) were similar between the 1G-DES and 2G-DES 
groups in all three different glycemic groups.
Clinical outcomes. Cumulative incidences of major clinical outcomes during the 2-year follow-up period 
are summarized in Tables 2, 3, and Fig. 1, and Supplementary information.
Prediabetes group. After the adjustment, the cumulative incidences of POCOs (adjusted hazard ratio 
[aHR]: 1.369; 95% confidence interval [CI] 1.044–1.720; p = 0.012), any repeat revascularization (aHR: 1.795; 
95% CI 1.280–2.518; p = 0.001), and ST (aHR: 2.637; 95% CI 1.370–5.077; p = 0.004) were significantly higher in 
the 1G-DES than that in the 2G-DES group.
Diabetes group. After the adjustment, the cumulative incidences of POCOs (aHR: 1.331; 95% CI 1.070–
1.657; p = 0.010), all-cause death (aHR: 1.534; 95% CI 1.115–2.112; p = 0.009), CD (aHR: 1.700; 95% CI 1.195–
2.448; p = 0.003), any repeat revascularization (aHR: 1.673; 95% CI 1.211–2.313; p = 0.002), and ST (aHR: 2.065; 
95% CI 1.100–3.876; p = 0.024) were significantly higher in the 1G-DES group than that in the 2G-DES group.
Normoglycemia group. After the adjustment, the cumulative incidences of POCOs, all-cause death, CD, 
Re-MI, all-cause death or MI, and any repeat revascularization were similar between the 1G-DES and 2G-DES 
groups. However, the cumulative incidence of ST (aHR: 3.262; 95% CI 1.226–8.678; p = 0.018) was significantly 
higher in the 1G-DES than that in the 2G-DES group.
1G‑DES group. Cumulative incidences of POCOs (aHR: 1.135; 95% CI 0.836–1.535; p = 0.417) and ST 
(aHR: 1.175; 95% CI 0.551–2.507; p = 0.677) were similar between prediabetes and diabetes groups. The cumula-
tive incidence of any repeat revascularization was significantly higher in the prediabetes than that in the nor-
moglycemia group (aHR: 1.858; 95% CI 1.027–3.359; p = 0.040). Cumulative incidences of POCOs (aHR: 1.667; 
95% CI 1.105–2.515; p = 0.015) and any repeat revascularization (aHR: 1.875; 95% CI 1.029–3.215; p = 0.038) 
were significantly higher in the diabetes than that in the normoglycemia group.
2G‑DES group. Cumulative incidences of POCOs (aHR: 1.116; 95% CI 0.962–1.294; p = 0.148) and ST 
(aHR: 1.546; 95% CI 0.942–2.538; p = 0.085) were similar between prediabetes and diabetes groups. However, 
cumulative incidences of Re-MI (aHR: 1.393; 95% CI 1.135–2.043; p = 0.032) and all-cause death or MI (aHR: 
1.224; 95% CI 1.023–1.524; p = 0.029) in the diabetes group were significantly higher than that in the prediabetes 
group. Cumulative incidences of POCOs (aHR: 1.294; 95% CI 1.078–1.553; p = 0.006), all-cause death (aHR: 
1.353; 95% CI 1.021–1.793; p = 0.035), CD (aHR: 1.392; 95% CI 1.004–1.930; p = 0.047), and all-cause death or 
MI (aHR: 1.425; 95% CI 1.132–1.794; p = 0.003) were significantly higher in the prediabetes than that in the 
normoglycemia group. Cumulative incidences of POCOs (aHR: 1.400; 95% CI 1.165–1.683; p < 0.001), all-cause 
death (aHR: 1.430; 95% CI 1.074–1.095; p = 0.014), CD (aHR: 1.471; 95% CI 1.055–2.052; p = 0.023), Re-MI 
(aHR: 1.694; 95% CI 1.161–2.472; p = 0.006), all-cause death or MI (aHR: 1.684; 95% CI 1.338–2.120; p < 0.001), 
any repeat revascularization (aHR: 1.362; 95% CI 1.031–1.769; p = 0.030), and ST (aHR: 2.068; 95% CI 1.125–
3.869; p = 0.014) were significantly higher in the diabetes than that in the normoglycemia group.
Table 4 shows independent predictors for POCOs and ST at the 2-year follow-up. Old age (≥ 65 years), male 
sex, low LVEF (< 40%), cardiogenic shock, cardiopulmonary resuscitation on admission, and multivessel disease 
were significant independent predictors for POCOs. Low LVEF and < 3 mm diameter of the deployed stent were 
independent predictors for ST in this study.
Discussion
The primary findings of this study are as follows: (1) in both prediabetes and diabetes groups, the cumulative 
incidences of POCOs, any repeat revascularization, and ST were higher in the 1G-DES than that in the 2G-DES; 
(2) in the diabetes group, the cumulative incidences of all-cause death and CD were higher in the 1G-DES than 
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(n = 4238) p value
Male, n (%) 367 (76.1) 2558 (80.2) 0.041 555 (72.4) 3276 (73.8) 0.398 539 (69.2) 3013 (71.7) 0.283
Age, years 61.6 ± 13.4 61.4 ± 13.0 0.836 64.0 ± 12.0 64.3 ± 12.4 0.488 63.4 ± 11.6 63.3 ± 11.6 0.823
LVEF, % 53.4 ± 11.9 52.9 ± 10.7 0.306 52.6 ± 12.4 52.3 ± 11.2 0.578 51.3 ± 12.1 51.2 ± 11.6 0.809
BMI, kg/m2 23.9 ± 2.8 23.8 ± 3.1 0.556 24.1 ± 3.1 24.1 ± 3.3 0.892 24.5 ± 3.1 24.5 ± 3.2 0.699
SBP, mmHg 129.9 ± 26.9 131.2 ± 27.8 0.354 130.4 ± 27.9 129.5 ± 27.7 0.421 130.5 ± 25.9 131.6 ± 28.1 0.319
DBP, mmHg 80.3 ± 16.7 80.6 ± 16.7 0.791 80.2 ± 16.1 78.7 ± 16.3 0.017 78.9 ± 15.5 79.1 ± 16.4 0.825
Cardiogenic shock, n (%) 16 (3.3) 126 (3.9) 0.612 41 (5.3) 203 (4.6) 0.351 18 (2.3) 190 (4.5) 0.004
CPR on admission, n (%) 6 (1.2) 154 (4.8)  < 0.001 19 (2.5) 217 (4.9) 0.002 10 (1.3) 167 (3.9)  < 0.001
STEMI, n (%) 283 (58.7) 1894 (59.4) 0.790 437 (57.0) 2576 (58.0) 0.580 438 (56.2) 2276 (53.7) 0.194
Primary PCI, n (%) 264 (93.3) 1825 (96.4) 0.014 407 (93.1) 2477 (96.2) 0.004 415/ (94.7) 2177/ (95.7) 0.404
NSTEMI, n (%) 199 (41.3) 1298 (40.7) 0.790 330 (43.0) 1862 (42.0) 0.580 341 (43.8) 1962 (46.3) 0.194
PCI within 24 h 144 (72.4) 1146 (88.3)  < 0.001 255 (77.3) 1592/ (85.5)  < 0.001 247/ (72.4) 1654/ (84.3)  < 0.001
Hypertension, n (%) 228 (47.3) 1333 (41.8) 0.022 393 (51.2) 2188 (49.3) 0.322 432 (55.5) 2427 (57.3) 0.348
Dyslipidemia, n (%) 36 (7.5) 271 (8.5) 0.481 17 (10.0) 524 (11.8) 0.178 117 (15.0) 623 (14.7) 0.826
Previous MI, n (%) 14 (2.9) 98 (3.1) 0.843 20 (2.6) 137 (3.1) 0.567 21 (2.7) 196 (4.6) 0.013
Previous PCI, n (%) 17 (3.5) 135 (4.2) 0.540 42 (5.5) 239 (5.4) 0.931 49 (6.3) 314 (7.4) 0.292
Previous CABG, n (%) 0 (0.0) 9 (0.3) 0.616 3 (0.4) 13 (0.3) 0.720 4 (0.5) 30 (0.7) 0.811
Previous CVA, n (%) 18 (3.7) 153 (4.8) 0.354 47 (6.1) 268 (6.0) 0.935 49 (6.3) 311 (7.3) 0.326
Previous HF, n (%) 2 (0.4) 18 (0.6) 0.678 8 (1.0) 50 (1.1) 0.839 18 (2.3) 62 (1.5) 0.087
Current smokers, n (%) 233 (48.3) 1441 (45.2) 0.191 309 (40.3) 1943 (43.8) 0.076 317 (40.7) 1731 (40.8) 0.968
Peak CK-MB, mg/dL 128.9 ± 149.4 139.0 ± 203.7 0.189 126.0 ± 204.3 138.3 ± 197.0 0.119 102.6 ± 152.9 106.3 ± 143.3 0.534
Peak troponin-I, ng/mL 39.5 ± 54.9 48.3 ± 75.2 0.002 40.7 ± 80.7 46.7 ± 107.5 0.072 37.7 ± 63.4 48.6 ± 94.8 0.001
NT-ProBNP, pg/mL 2307.6 ± 4254.5 1879.2 ± 3457.2 0.035 2194.5 ± 4071.7 2070.7 ± 3721.1 0.431 2549.2 ± 4658.0 2414.0 ± 5379.2 0.468
Hs-CRP, mg/dL 15.4 ± 83.9 7.9 ± 28.5  < 0.001 12.8 ± 35.4 9.8 ± 46.2 0.038 16.3 ± 62.6 11.5 ± 43.7 0.039
Serum creatinine, mg/L 1.08 ± 0.96 1.03 ± 0.99 0.268 1.12 ± 1.02 1.11 ± 1.50 0.926 1.26 ± 2.50 1.18 ± 1.66 0.352
Total cholesterol, mg/dL 183.4 ± 40.2 180.6 ± 40.8 0.161 187.7 ± 43.2 186.0 ± 44.1 0.332 186.3 ± 47.6 181.1 ± 48.4 0.005
Triglyceride, mg/L 116.4 ± 75.8 118.3 ± 88.0 0.625 118.4 ± 74.4 131.5 ± 101.1  < 0.001 153.4 ± 124.4 157.1 ± 136.7 0.459
HDL cholesterol, mg/L 44.7 ± 12.7 44.4 ± 15.2 0.616 44.6 ± 12.7 43.4 ± 15.1 0.022 43.3 ± 22.9 41.8 ± 14.2 0.090
LDL cholesterol, mg/L 117.2 ± 34.8 114.6 ± 36.0 0.120 120.4 ± 37.4 118.8 ± 45.0 0.304 116.8 ± 42.4 112.0 ± 38.5 0.003
Diabetes management
Diet, n (%) 53 (6.8) 306 (7.2) 0.762
Oral agent, n (%) 469 (60.2) 2488 (58.7) 0.435
Insulin, n (%) 49 (6.3) 252 (5.9) 0.710
Untreated, n (%) 208 (26.7) 1192 (28.1) 0.413
Discharge medications
Aspirin, n (%) 454 (94.2) 3092 (96.9) 0.002 724 (94.4) 4276 (96.3)  < 0.001 726 (93.2) 4072 (96.1)  < 0.001
Clopidogrel, n (%) 477 (99.0) 2573 (80.6)  < 0.001 746 (97.3) 3810 (85.8)  < 0.001 757 (97.2) 3624 (85.5)  < 0.001
Ticagrelor, n (%) 1 (0.2) 382 (12.0)  < 0.001 4 (0.5) 382 (8.6)  < 0.001 8 (1.0) 328 (7.7)  < 0.001
Prasugrel, n (%) 0 (0.0) 198 (6.2)  < 0.001 4 (0.5) 203 (4.6)  < 0.001 2 (0.3) 204 (4.8)  < 0.001
Cilostazole, n (%) 137 (28.4) 449 (14.1)  < 0.001 223 (29.1) 848 (19.1)  < 0.001 231 (29.7) 830 (19.6)  < 0.001
Beta-blockers, n (%) 380 (78.8) 2651 (83.1) 0.022 608 (79.3) 3680 (82.9)  < 0.001 594 (76.3) 3522 (83.1)  < 0.001
ACEIs, n (%) 308 (63.9) 1843 (57.8) 0.011 444 (57.9) 2404 (54.2) 0.012 438 (56.2) 2176 (51.3) 0.012
ARBs, n (%) 91 (18.9) 765 (24.0) 0.014 185 (24.1) 1133 (25.5) 0.004 189 (24.3) 1240 (29.3) 0.004
CCBs, n (%) 37 (7.7) 181 (5.7) 0.083 55 (7.2) 245 (5.5) 0.248 68 (8.7) 319 (7.5) 0.248
Lipid lowering agents 393 (81.5) 2876 (90.1)  < 0.001 618 (80.6) 3937 (88.7)  < 0.001 601 (77.2) 3645 (86.0)  < 0.001
IRA
Left main, n (%) 7 (1.5) 54 (1.7) 0.849 19 (2.5) 77 (1.7) 0.670 16 (2.1) 79 (1.9) 0.670
LAD, n (%) 257 (53.3) 1603 (50.2) 0.207 373 (48.6) 2179 (49.1) 0.275 377 (48.4) 1961 (46.3) 0.275
LCx, n (%) 81 (16.8) 523 (16.4) 0.819 136 (17.7) 728 (16.4) 0.174 147 (18.9) 715 (16.9) 0.174
RCA, n (%) 136 (28.2) 1010 (31.7) 0.140 239 (31.2) 1454 (32.8) 0.024 238 (30.6) 1474 (34.8) 0.024
Treated vessel
Left main, n (%) 17 (3.5) 84 (2.6) 0.293 27 (3.5) 129 (2.9) 0.237 30 (3.9) 129 (3.0) 0.237
LAD, n (%) 291 (60.4) 1883 (59.0) 0.570 460 (60.0) 2591 (58.4) 0.994 458 (58.8) 2491 (58.8) 0.994
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that in the 2G-DES; (3) in the normoglycemia group, the cumulative incidence of ST was higher in the 1G-DES 
than that in the 2G-DES; and (4) in two different stent generations, the cumulative incidence of POCOs was 
similar between the prediabetes and diabetes groups. However, in the 2G-DES group, the cumulative incidences 
of Re-MI and all-cause death or MI were higher in the diabetes group than that in the prediabetes group.
Hyperglycemia, elevated free fatty acid level, and increased amount of circulating glucosylated serum products 
can accelerate atherosclerosis and vascular injury in patients with diabetes by inducing endothelial dysfunction 
and vascular  inflammation16. Although previous reports demonstrated that the higher rates of repeat revascu-
larizations and mortality after PCI in patients with diabetes are caused by restenosis and disease  progression4–6, 
comparative clinical outcomes between prediabetes and diabetes were not well illuminated especially, between 
1G-DES and 2G-DES. Some recent reports showed that prediabetes is associated with poorer clinical outcomes 
including cardiovascular mortality and patients with prediabetes and diabetes have similar higher risk profiles 
compared with  normoglycemia13,14,17.
Although DES improved outcomes of high-risk patients by reducing the rate of restenosis as compared with 
 BMS18,19, ST remains a major concern after the DES implantation, especially in  diabetes4. Relative superiority 
between the 1G-DES and 2G-DES in patients with AMI and diabetes remains controversial, and most previ-
ous studies were not performed during the prediabetes  stage10,20,21. In our study, the cumulative incidence of 
POCOs was significantly higher in the 1G-DES than that in the 2G-DES in both prediabetes and diabetes 
groups. Moreover, in two different stent generations, the cumulative incidence of POCOs was similar between 
the prediabetes and diabetes groups (Table 3). In a substudy of the multicenter BIO-RESORT (BIOdegradable 
Polymer and DuRable Polymer Drug-eluting Stents in an All COmeRs PopulaTion)  trial13, comparative clini-
cal outcomes were similar between prediabetes and diabetes (11.1% vs. 10.5%). Von Birgelen et al.22 reported 
the results of the BIO-RESORT Silent Diabetes Study. In their study, the cumulative incidence of major adverse 
cardiac events was different between patients with prediabetes (5.5%) and normoglycemia (3.0%) (Log-rank, 
Table 1.  Baseline clinical, laboratory, and procedural characteristics. Values are means ± SD or numbers 
and percentages. The p values for continuous data were obtained from the analysis of variance. The p values 
for categorical data were obtained from the chi-square or Fisher’s exact test. PCI percutaneous coronary 
intervention, BMS bare-metal stents, 1G first-generation, 2G second-generation, DES drug-eluting stents, 
LVEF left ventricular ejection fraction, BMI body mass index, CPR cardiopulmonary resuscitation, MI 
myocardial infarction, CABG coronary artery bypass graft, CVA cerebrovascular accidents, HF heart failure, 
CK-MB creatine kinase myocardial band, NT-ProBNP N-terminal pro-brain natriuretic peptide, Hs-CRP high-
sensitivity-C-reactive protein, HDL high-density lipoprotein, LDL low-density lipoprotein, ACEIs angiotensin 
converting enzyme inhibitors, ARBs angiotensin receptor blockers, CCBs calcium channel blockers, IRA 
infarct-related artery, ACC/AHA American College of Cardiology/American Heart Association, CAD coronary 
artery disease, SES sirolimus-eluting stent, PES paclitaxel-eluting stent, ZES zotarolimus-eluting stent, EES 
everolimus-eluting stent, BES biolimus-eluting stent, IVUS intravascular ultrasound, OCT optical coherence 
tomography, FFR fractional flow reserve.
Variables


















(n = 4238) p value
RCA, n (%) 169 (35.1) 1182 (37.0) 0.418 292 (38.1) 1744 (39.3) 0.252 313 (40.2) 1799 (42.4) 0.252
ACC/AHA lesion type
Type B1, n (%) 82 (17.0) 424 (13.3) 0.027 120 (15.6) 597 (13.5) 0.009 124 (15.9) 530 (12.5) 0.009
Type B2, n (%) 153 (31.7) 1064 (33.3) 0.500 248 (32.3) 1425 (32.1) 0.180 231 (29.7) 1362 (32.1) 0.180
Type C, n (%) 168 (34.9) 1424 (44.6)  < 0.001 284 (37.0) 1957 (44.1)  < 0.001 277 (35.6) 1942 (45.8)  < 0.001
Extent of CAD
1-vessel, n (%) 229 (47.5) 1744 (54.7) 0.003 327 (42.6) 2234 (50.3)  < 0.001 280 (35.9) 1807 (42.6)  < 0.001
2-vessel, n (%) 166 (34.4) 962 (30.1) 0.057 251 (32.7) 1398 (31.5) 0.847 265 (34.0) 1426 (33.6) 0.847
 ≥ 3-vessel, n (%) 87 (18.0) 485 (15.2) 0.121 189 (24.6) 806 (18.2)  < 0.001 234 (30.0) 1005 (23.7)  < 0.001
DESs
SES, n (%) 225 (46.7) 330 (43.0) 352 (45.2)
PES, n (%) 257 (53.3) 437 (57.0) 427 (54.8)
ZES, n (%) 1015 (31.8) 1529 (34.5) 1478 (34.9)
EES, n (%) 1625 (50.9) 2278 (51.3) 2194 (51.8)
BES, n (%) 525 (16.4) 600 (13.5) 536 (12.6)
Others, n (%) 26 (0.8) 31 (0.7) 30 (0.7)
IVUS 119 (24.7) 682 (21.4) 0.110 185 (24.1) 1038 (23.4) 0.533 156 (20.0) 894 (21.1) 0.533
OCT 0 (0.0) 24 (0.8) 0.064 1 (0.1) 34 (0.8) 0.010 0 (0.0) 31 (0.7) 0.010
FFR 1 (0.2) 30 (0.9) 0.114 1 (0.1) 60 (1.4) 0.026 2 (0.3) 46 (1.1) 0.026
Stent diameter, mm 3.16 ± 0.42 3.16 ± 0.43 0.907 3.14 ± 0.42 3.14 ± 0.42 0.098 3.07 ± 0.39 3.10 ± 0.42 0.098
Stent length, mm 25.9 ± 7.8 27.1 ± 11.4 0.004 26.0 ± 7.2 26.9 ± 11.5 0.003 26.5 ± 7.9 27.5 ± 11.8 0.003
Number of stent 1.50 ± 0.84 1.42 ± 0.75 0.053 1.55 ± 0.84 1.48 ± 0.80 0.469 1.59 ± 0.90 1.56 ± 0.84 0.469
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(n = 3191) Log-rank
Unadjusted
HR (95% CI) p value
Adjusteda
HR (95% CI) p value
POCOs 41 (8.6) 193 (6.7) 0.098 1.328 (0.948–1.861) 0.099 1.216 (0.854–1.730) 0.278
All-cause death 22 (4.6) 80 (2.7) 0.025 1.705 (1.063–2.734) 0.027 1.504 (0.914–2.474) 0.109
Cardiac death 17 (3.6) 59 (1.9) 0.027 1.825 (1.064–3.131) 0.029 1.487 (0.838–2.639) 0.176
Re-MI 8 (1.7) 42 (1.5) 0.675 1.175 (0.551–2.505) 0.676 1.180 (0.532–2.619) 0.665
All-cause death or MI 27 (5.6) 116 (4.0) 0.088 1.438 (0.945–2.187) 0.090 1.307 (0.843–2.026) 0.232
Any repeat revascu-
larization 17 (3.6) 85 (3.1) 0.444 1.225 (0.728–2.063) 0.444 1.118 (0.645–1.938) 0.692
Stent thrombosis 







(n = 4438) Log-rank
Unadjusted
HR (95% CI) p value
Adjustedb HR (95% 
CI) p value
POCOs 91 (12.0) 371 (8.9) 0.007 1.372 (1.091–1.726) 0.007 1.369 (1.044–1.720) 0.012
All-cause death 43 (5.6) 185 (4.4) 0.121 1.299 (0.932–1.810) 0.122 1.350 (0.939–1.845) 0.110
Cardiac death 34 (4.5) 140 (3.3) 0.098 1.370 (0.942–1.993) 0.100 1.364 (0.916–1.963) 0.132
Re-MI 19 (2.5) 80 (2.0) 0.305 1.299 (0.787–2.142) 0.306 1.293 (0.780–2.137) 0.316
All-cause death or MI 52 (6.8) 258 (6.1) 0.467 1.117 (0.829–1.505) 0.468 1.114 (0.824–1.502) 0.483
Any repeat revascu-
larization 46 (6.3) 144 (3.6) 0.001 1.780 (1.277–2.481) 0.001 1.795 (1.280–2.518) 0.001
Stent thrombosis 







(n = 4238) Log-rank
Unadjusted
HR (95% CI) p value
Adjustedc
HR (95% CI) p value
POCOs 107 (13.9) 410 (10.3) 0.003 1.373 (1.110–1.699) 0.003 1.331 (1.070–1.657) 0.010
All-cause death 50 (6.5) 189 (4.7) 0.037 1.390 (1.018–1.899) 0.038 1.534 (1.115–2.112) 0.009
Cardiac death 42 (5.4) 144 (3.5) 0.012 1.544 (1.095–2.178) 0.013 1.700 (1.195–2.448) 0.003
Re-MI 24 (3.2) 105 (2.8) 0.474 1.176 (0.754–1.832) 0.475 1.318 (0.833–2.085) 0.237
All-cause death or MI 64 (8.3) 296 (7.4) 0.377 1.129 (0.862–1.480) 0.378 1.290 (0.977–1.703) 0.073
Any repeat revascu-
larization 51 (6.9) 160 (4.3) 0.001 1.661 (1.212–2.276) 0.002 1.673 (1.211–2.313) 0.002
Stent thrombosis 
(probable or definite) 16 (2.1) 40 (0.9) 0.007 2.189 (1.226–3.909) 0.008 2.065 (1.100–3.876) 0.024
Table 2.  Clinical outcomes between 1G-DES and 2G-DES at 2 years. POCOs patient-oriented composite 
outcomes defined as a composite of all-cause deaths, Re-MI or any repeat revascularization, Re-MI 
recurrent myocardial infarction, LVEF left ventricular ejection fraction, DBP diastolic blood pressure, CPR 
cardiopulmonary resuscitation, PCI percutaneous coronary intervention, hs-CRP high-sensitivity-C-reactive 
protein, HDL high-density lipoprotein, LDL low-density lipoprotein, ACEI angiotensin converting enzyme 
inhibitor, ARB angiotensin receptor blockers, IRA infarct-related artery, RCA right coronary artery, ACC/AHA 
American College of Cardiology/American Heart Association, IVUS intravascular ultrasound, OCT optical 
coherence tomography, FFR fractional flow reserve. a Adjusted by male, age, CPR on admission, primary PCI, 
PCI within 24hours, hypertension, peak troponin-I, aspirin, clopidogrel, ticagrelor, prasugrel, cilostazole, beta-
blocker, ACEI, ARB, lipid lowering agent, ACC/AHA type B1/C lesions, 1-vessel disease, stent length (p vales 
of these covariates were < 0.05 or having predictive values). b Adjusted by male, age, DBP, cardiogenic shock, 
CPR on admission, primary PCI, PCI within 24 h, hs-CRP, triglyceride, HDL-cholesterol, aspirin, clopidogrel, 
ticagrelor, prasugrel, cilostazole, beta-blocker, lipid lowering agents, ACC/AHA type C lesions, 1-vessel 
disease, ≥ 3-vessel disease, FFR, stent length, number of stent (p vales of these covariates were < 0.05 or having 
predictive values). c Adjusted by male, age, cardiogenic shock, CPR on admission, PCI within 24hours, previous 
MI, peak troponin-I, hs-CRP, total cholesterol, LDL-cholesterol, aspirin, clopidogrel, ticagrelor, prasugrel, 
cilostazole, beta-blocker, ACEI, ARB, lipid lowering agent, IRA (RCA), ACC/AHA type B1/C lesions, OCT, 
FFR, stent length (p vales of these covariates were < 0.05 or having predictive values).
p = 0.07). As mentioned, despite the combination of new platforms, more biocompatible polymers were utilized 
in 2G-DES, the relative superiority between 1G- and 2G-DESs in patients with diabetes remains  controversial8–11. 
In the SPIRIT V Diabetic  Study10, everolimus-eluting stent (EES) was superior to paclitaxel-eluting stent (PES) 
for in-stent late loss at 9 months. The composite death, MI, and TVR rates were the same in the two groups at 
1 year. Bavishi et al.9 reported that EES showed significantly lower incidence rates of MACEs by 18% and ST 
by 46% as compared with the 1G-DES. Moreover, the EES showed a trend toward reduced incidence rates of 
target lesion revascularization (TLR) and TVR (p = 0.05). In this study, based on the cumulative incidences of 
POCOs, any revascularization rate was significantly higher in the 1G-DES than that in the 2G-DES group in 
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both prediabetes and diabetes group. Therefore, the major clinical outcomes of our study could reflect the meta-
analysis results of Bavishi et al.’s  study9.
The overall rate of ST was also higher in the 1G-DES than in the 2G-DES in all three different glycemic groups 
(prediabetes [1.8% vs. 0.7%, log-rang p = 0.001], diabetes [2.1% vs. 0.9%, log-rank p = 0.007], and normoglycemia 
[1.5% vs. 0.5%, log-rank p = 0.009]). With regard to prediabetes, follow-up data on the comparative long-term 
effects of 1G-DES and 2G-DES implantation were limited. According to Bavishi et al.’s  report9, EES reduced the 
incidence of ST by 46% (RR: 0.54, 95% CI 0.35–0.82) as compared with the 1G-DES in patients with diabetes. The 
cumulative incidence of ST also higher in the 1G-DES than that in the 2G-DES in patients with normoglycemia. 
Our result is consistent with the result of Nakatsuma et al.  study23. This low cumulative incidence of 2G-DES may 
be related with relatively thin stent struts (50–90 μm) and improved ability for deliverability while maintaining 
an adequate radial  strength24 and more compatible and thromboresistant than those in the 1G-DES25. However, 
in our study, the occurrence of ST was high within 6 months after index PCI (Supplementary Fig. 1). Therefore, 
we cannot completely exclude the possibility that ST was associated with PCI  procedure26. Even though IVUS-
guided27 or functional flow reserve (FFR)-guided  PCI28 could reduce MACE rate, the number of PCI base on 
these intracoronary image- or functional study-based PCI were less than 30% in our study. Unfortunately, 
currently under the Korea’s health insurance system, the reimbursement program for the use of IVUS, optical 
coherence of tomography, or fractional flow reserve during the PCI is very limited or  absent29.
Interestingly, comparative clinical outcomes of the two different stent generations according to glycemic 
status showed some different results (Table 3). Different clinical outcomes among three different glycemic states 
(normoglycemia, prediabetes, and diabetes) were more prominent in the 2G-DES rather 1G-DES. According 
to advances in interventional skill, devices, and antiplatelet  agents5,6, 2G-DES showed decreased incidences of 
all-cause death (aHR: 1.534; 95% CI 1.115–2.112; p = 0.009) and CD (aHR: 1.700; 95% CI 1.195–2.448; p = 0.003) 
compared with 1G-DES in diabetes group after adjustment (Table 2). Bavishi et al.9 showed that there was a 
trend towards reduction in all-cause mortality with zotarolimus compared to 1G-DES (6.3% vs. 7.2%, relative 
risk: 0.74; 95% CI 0.55–1.00; p = 0.05) in their meta-analysis. However, the cumulative incidences of all clinical 
outcomes were significantly higher in the diabetes than that in the normoglycemia group. These results may 
reflect hazardous effects of diabetes are sustained even in the era of 2G-DES.
In our study, in the 1G-DES, the primary and secondary end-points were similar between the prediabetes and 
diabetes groups. However, in the 2G-DES, the cumulative incidences of Re-MI (aHR: 1.393; 95% CI 1.135-2.043; 
p = 0.032) and all-cause death or MI (aHR: 1.224; 95% CI 1.023–1.524; p = 0.029) were significantly higher in the 
diabetes group than that in the prediabetes group. Although the precise mechanisms of the higher incidence of 
Re-MI in diabetes group are not fully known, one  report30 suggested that the association between diabetes and 
Re-MI may be related with a direct effect of diabetes. According to recent  reports14,31, the cumulative incidence 
of Re-MI of the diabetes group was significantly higher than that of the prediabetes group (aHR: 1.884; 95% CI 
1.201–2.954; p = 0.006 or aHR: 1.660; 95% CI 1.000–2.755; p = 0.020).
More than 50 high-volume university or community hospitals in South Korea participated in this study. The 
limited reports on the impact of stent generation on long-term clinical outcomes in AMI patients with prediabetes 
or diabetes were the motivation for the current study. Thus, we believe that our study may provide significant 
information to interventional cardiologists who perform PCI in patients with AMI with prediabetes or diabetes.
This study has several limitations. First, because the study population was obtained from the Korea AMI 
registry data, some data might be under-reported and/or missed. Second, it is necessary for diagnosing diabetes 
to check an HbA1c level ≥ 6.5%, FPG ≥ 126 mg/dL (7.0 mmol/L), and/or RPG ≥ 200 mg/dL (11.1 mmol/L) by 
repeat testing. If first glycemic status was diabetes and second was prediabetes, or first glycemic status was pre-
diabetes and second was normoglycemia, and this is particularly important in patients with AMI, because such 
patients reveal hyperglycemia in acute phase. However, in this study, the definitions of prediabetes and diabetes 
were not based on repeat testing. Moreover, considering the limitation of HbA1c, any other diagnostic tests for 
diabetes including oral glucose tolerance test are needed for a finer classification. However, detailed information 
on this variable was not included in the KAMIR. Hence, the results of this study can be altered based on other 
diagnostic tests and which directly influences the assignment of participants, and this factor may have served as 
an important bias in this  study32. Third, the duration and types of antidiabetic treatment are major determinants 
after PCI in patents with prediabetes or diabetes. However, this study was conducted based on discharge medica-
tions, and owing to limitation of registry study, we did not precisely know the adherence or non-adherence of 
enrolled patients to antidiabetic drugs during the follow-up period. Therefore, this may act as an important bias 
in this study. Fourth, 2G-DES consisted of durable-polymer-coated DES and biodegradable-polymer-coated 
DES. The number of biodegradable-polymer DES (BES) was highest in the normoglycemia group (prediabetes: 
600/4438 (13.5%); diabetes: 536/4238 (12.6%); normoglycemia: 525/3191 (16.5%); p < 0.001) (Table 1). Although 
this number was not significantly different between prediabetes and diabetes (p = 0.226), this division may be 
not reasonable and the composition of 2G-DES could be changed according to other types of utilized newer-
generation DES. Therefore, other types of newer-generation DES could influence the outcome of our study. Fifth, 
although multivariate analysis was performed to strengthen our results, variables not included in the KAMIR may 
have affected the study outcomes. Sixth, the 2-year follow-up period in this study was relatively short in order 
to determine the long-term major clinical outcomes; therefore, data from studies with longer follow-up periods 
are required. Seventh, this study retrospectively enrolled the patients who underwent PCI from 2005–2015. The 
development of stent platform, potent antiplatelet drugs, and use of intracoronary imaging and improvement 
of procedural skills, all these factors substantially affect the clinical outcomes. Therefore, these factors could be 
also important bias of this study. Finally, although 2G-DES are considered the safest in the general population, 
this study confirms that in a select and growing population.
In conclusion, in this study, we observed that 2G-DES was more effective than 1G-DES in reducing POCOs, 
any repeat revascularization and ST in both prediabetes and diabetes group. Moreover, in two different stent 
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Group B1 prediabetes 
(n = 767) Log-rank
Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
POCOs 41 (8.6) 91 (12.0) 0.072 1.400 (1.968–2.024) 0.074 1.483 (0.985–2.232) 0.059
All-cause death 22 (4.6) 43 (5.6) 0.422 1.234 (0.738–2.062) 0.423 1.227 (0.675–2.033) 0.502
Cardiac death 17 (3.6) 34 (4.5) 0.433 1.261 (0.705–2.257) 0.435 1.455 (0.721–2.935) 0.295
Re-MI 8 (1.7) 19 (2.5) 0.334 1.498 (0.656–3.422) 0.337 1.748 (0.685–4.464) 0.243
All-cause death or MI 27 (5.6) 52 (6.8) 0.412 1.215 (0.763–1.933) 0.413 1.194 (0.707–1.919) 0.507
Any repeat revascularization 17 (3.6) 46 (6.3) 0.053 1.719 (0.986–2.999) 0.056 1.858 (1.027–3.359) 0.040





Group C1 diabetes 
(n = 779) Log-rank
Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
POCOs 41 (8.6) 107 (13.9) 0.007 1.630 (1.137–2.336) 0.008 1.667 (1.105–2.515) 0.015
All-cause death 22 (4.6) 50 (6.5) 0.168 1.420 (0.860–2.345) 0.170 1.451 (0.797–2.639) 0.164
Cardiac death 17 (3.6) 42 (5.4) 0.130 1.540 (0.877–2.705) 0.133 1.652 (0.815–3.349) 0.129
Re-MI 8 (1.7) 24 (3.2) 0.118 1.873 (0.841–4.169) 0.124 2.500 (0.971–6.441) 0.058
All-cause death or MI 27 (5.6) 64 (8.3) 0.084 1.483 (0.946–2.325) 0.086 1.496 (0.885–2.531) 0.072
Any repeat revascularization 17 (3.6) 51 (6.9) 0.022 1.878 (1.084–3.251) 0.024 1.875 (1.029–3.215) 0.038







(n = 779) Log-rank
Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
POCOs 91 (12.0) 107 (13.9) 0.285 1.165 (0.881–1.540) 0.285 1.135 (0.836–1.535) 0.417
All-cause death 43 (5.6) 50 (6.5) 0.500 1.151 (0.765–1.730) 0.500 1.166 (0.731–1.860) 0.488
Cardiac death 34 (4.5) 42 (5.4) 0.385 1.221 (0.777–1.919) 0.386 1.137 (0.678–1.909) 0.627
Re-MI 19 (2.5) 24 (3.2) 0.462 1.253 (0.686–2.287) 0.463 1.148 (0.599–2.199) 0.678
All-cause death or MI 52 (6.8) 64 (8.3) 0.283 1.221 (0.847–1.761) 0.284 1.189 (0.788–1.757) 0.410
Any repeat revascularization 46 (6.3) 51 (6.9) 0.663 1.093 (0.733–1.627) 0.663 1.035 (0.681–1.574) 0.872







Prediabetes (n = 4438) Log-rank
Unadjusted Adjustedb
HR (95% CI) p value HR (95% CI) p value
POCOs 193 (6.7) 371 (8.9)  < 0.001 1.388 (1.167–1.650)  < 0.001 1.294 (1.078–1.553) 0.006
All-cause death 80 (2.7) 185 (4.4)  < 0.001 1.642 (1.263–2.134)  < 0.001 1.353 (1.021–1.793) 0.035
Cardiac death 59 (1.9) 140 (3.3) 0.001 1.693 (1.249–2.295) 0.001 1.392 (1.004–1.930) 0.047
Re-MI 42 (1.5) 80 (2.0) 0.121 1.342 (0.924–1.950) 0.122 1.288 (0.876–1.894) 0.198
All-cause death or MI 116 (4.0) 258 (6.1)  < 0.001 1.578 (1.268–1.965)  < 0.001 1.425 (1.132–1.794) 0.003
Any repeat revascularization 85 (3.1) 144 (3.6) 0.206 1.189 (0.909–1.554) 0.206 1.223 (0.923–1.619) 0.161







(n = 4238) Log-rank
Unadjusted Adjustedb
HR (95% CI) p value HR (95% CI) p value
POCOs 193 (6.7) 410 (10.3)  < 0.001 1.566 (1.320–1.859)  < 0.001 1.400 (1.165–1.683)  < 0.001
All-cause death 80 (2.7) 189 (4.7)  < 0.001 1.748 (1.346–2.271)  < 0.001 1.430 (1.074–1.095) 0.014
Cardiac death 59 (1.9) 144 (3.5)  < 0.001 1.815 (1.341–2.457)  < 0.001 1.471 (1.055–2.052) 0.023
Re-MI 42 (1.5) 105 (2.8) 0.001 1.829 (1.278–2.616) 0.001 1.694 (1.161–2.472) 0.006
All-cause death or MI 116 (4.0) 296 (7.4)  < 0.001 1.885 (1.521–2.336)  < 0.001 1.684 (1.338–2.120)  < 0.001
Any repeat revascularization 85 (3.1) 160 (4.3) 0.018 1.370 (1.053–1.783) 0.019 1.362 (1.031–1.769) 0.030







(n = 4238) Log-rank
Unadjusted Adjustedb
HR (95% CI) p value HR (95% CI) p value
POCOs 371 (8.9) 410 (10.3) 0.046 1.153 (1.002–1.327) 0.046 1.116 (0.962–1.294) 0.148
All-cause death 185 (4.4) 189 (4.7) 0.531 1.067 (0.871–1.307) 0.531 1.109 (0.887–1.386) 0.365
Cardiac death 140 (3.3) 144 (3.5) 0.543 1.075 (0.852–1.356) 0.544 1.062 (0.822–1.334) 0.644
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generations, and the cumulative incidence of POCOs was similar between the prediabetes and diabetes groups. 
However, further studies regarding the most advanced DES technology joined with the most advanced anti-
thrombotic regimen are needed to confirm these results.
Methods
Study population. A total of 45,322 patients with AMI who underwent successful stent implantation, 
including patients with DM aged ≥ 30 years at the onset of diabetes, from November 2005 to June 2015 in the 
KAMIR, were evaluated. Details of the registry can be found at the KAMIR website (http:// www. kamir. or. kr) 33. 
Among them, patients with incomplete laboratory results (n = 9081, 20.0%), those who were lost to follow-up 
(n = 2175, 4.8%), those with unidentified blood hemoglobin (Hb) A1c and blood glucose level results (n = 13,931, 
30.7%), those with different generations of stents were deployed in the same patients (n = 40, 0.1%), those who 
received dual antiplatelet therapy (DAPT) less than 12 months (n = 5438, 12.0%), and those who received BMS 
(n = 762, 1.7%). Finally, a total of 13,895 patients with AMI who underwent successful implantation were con-
sidered for inclusion. Patients were classified into normoglycemia (group A: 3673; 26.4%), prediabetes (group 
B: 5205; 37.5%), and diabetes (group C: 5017; 36.1%) (Table  1). Subsequently, all three groups were further 
divided into 1G-DES (group A1, group B1, and group C1) and 2G-DES groups (group A2, group B2, and group 
C2) (Fig. 2). The study protocol was approved by the institutional review board of each participating center and 
the Chonnam National University Hospital Institutional Review Board ethics committee approved (approval 
number: CNUH-2011-172) the study protocol. The study has been performed in accordance with the ethical 
standards laid down in the 1975 Declaration of Helsinki. All persons gave their written informed consent prior 
to their inclusion in the study. All 13,895 patients completed the 2-year clinical follow-up by face-to-face inter-
views, phone calls, or medical chart review. All clinical events were evaluated by an independent event adjudi-
Table 3.  Two-year clinical outcomes according to the different glycemic status. POCOs patient-oriented 
composite outcomes defined as a composite of all-cause deaths, Re-MI or any repeat revascularization, 
Re-MI recurrent myocardial infarction, LVEF left ventricular ejection fraction, BMI body mass index, SBP 
systolic blood pressure, DBP diastolic blood pressure, MI myocardial infarction, PCI percutaneous coronary 
intervention, CABG coronary artery bypass graft, HF heart failure, CVA cerebrovascular accidents, CK-MB 
creatine kinase myocardial band, NT-ProBNP N-terminal pro-brain natriuretic peptide, HDL high-density 
lipoprotein, LDL low-density lipoprotein, ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin 
receptor blockers, CCBs calcium channel blockers, IRA infarct-related artery, RCA right coronary artery, ACC/
AHA American College of Cardiology/American Heart Association, FFR fractional flow reserve. a Adjusted by 
male, age, LVEF, BMI, cardiogenic shock, hypertension, dyslipidemia, previous HF, current smoker, CK-MB, 
ACEIs, 1-vessel, ≥ 3-vessel disease, triglyceride, stent diameter (p vales of these covariates were < 0.005 or 
having predictive values). b Adjusted by male, age, LVEF, BMI, DBP, STEMI, hypertension, dyslipidemia, 
previous MI, previous PCI, previous CVA, CK-MB, serum creatinine, total cholesterol, triglyceride, HDL-
cholesterol, LDL-cholesterol, clopidogrel, ticagrelor, cilostazole, ACEIs, ARBs, CCB, lipid lowering agents, 
RCA (treated vessel), 1-vessel disease, ≥ 3-vessel disease, stent diameter, number of stent (p vales of these 







(n = 4238) Log-rank
Unadjusted Adjustedb
HR (95% CI) p value HR (95% CI) p value
All-cause death or MI 258 (6.1) 296 (7.4) 0.033 1.197 (1.013–1.415) 0.034 1.224 (1.023–1.524) 0.029
Any repeat revascularization 144 (3.6) 160 (4.3) 0.203 1.157 (0.924–1.449) 0.204 1.088 (0.863–1.373) 0.474
ST (definite or probable) 29 (0.7) 40 (0.9) 0.129 1.445 (0.896–2.331) 0.131 1.546 (0.942–2.538) 0.085
Figure 1.  Kaplan–Meier analysis of the incidence of POCOs.
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Table 4.  Independent predictors for POCOs and stent thrombosis at 2 years. 1G first-generation, 2G second-
generation, DES drug-eluting stent, POCOs patient-oriented composite outcomes, HR hazard ratio, LVEF left 
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A total of 45,322 patients with AMI, including patients with diabetes aged ≥ 30 years at the onset of 
diabetes, from November 2005 to June 2015 in the KAMIR, were evaluated
Exclusion
- Incomplete laboratory results (n = 9081)
- Lost to follow-up (n = 2175)
- Unidentified blood HbA1c and blood glucose results (n = 13,931)
- Different generation of stents were deployed in the same patients (n = 40)
- Duration of DAPT < 12months (n = 5438)
- Bare-metal stents (n = 762)










1G-DES (n = 482)    Group A1
2G-DES (n = 3191) Group A2
1G-DES (n = 767)    Group B1
2G-DES (n = 4438) Group B2
1G-DES (n = 779)    Group C1
2G-DES (n = 4238) Group C2
Figure 2.  Study flow chart. AMI, acute myocardial infarction; KAMIR, Korea AMI Registry; HbA1c, 
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cating committee. The event adjudication processes have been described in a previous publication of KAMIR 
 investigators34.
Percutaneous coronary intervention and medical treatment. Before PCI, all patients were admin-
istered loading doses of aspirin 200–300 mg and clopidogrel 300–600 mg; alternatively, ticagrelor 180 mg or 
prasugrel 60 mg was administered. PCI was performed via the femoral or radial approach after an intravenous 
bolus dose of heparin (50–100 U/kg) to achieve an activated clotting time of > 250 s. DAPT (a combination of 
aspirin 100 mg/day with clopidogrel 75 mg/day or ticagrelor 90 mg twice daily or prasugrel 5–10 mg/day) was 
recommended for > 12 months for patients who underwent PCI. Triple antiplatelet therapy (TAPT: cilostazol 
100 mg twice daily in addition to DAPT) was left to the discretion of the individual operators. Diagnostic coro-
nary angiography and PCI were performed using standard  guideline35.
Study definitions and clinical outcomes. Glycemic status was determined based on medical history 
and glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and random plasma glucose (RPG) levels at 
the index hospitalization. According to the American Diabetes Association clinical practice  recommendation32, 
prediabetes was defined as an HbA1c of 5.7–6.4% and an FPG of 100–125 mg/dL (5.6–6.9 mmol/L). Diabetes 
was categorized as either known diabetes defined as ongoing medical treatment for diabetes (insulin or antidia-
betics), or newly diagnosed diabetes, defined as an HbA1c level ≥ 6.5%, FPG ≥ 126 mg/dL (7.0 mmol/L), and/
or RPG ≥ 200 mg/dL (11.1 mmol/L). If the admission electrocardiogram of patients who complained of chest 
pain showed ST-segment elevations in at least two contiguous leads of ≥ 2 mm (0.2 mV) in men, or ≥ 1.5 mm 
(0.15 mV) in women in leads V2–V3 and/or ≥ 1 mm (0.1 mV) in other contiguous chest leads or limb leads or 
new-onset left bundle branch block, the patients were considered to have  STEMI36, whereas patients who did not 
show persistent ST-segment elevation with increased cardiac biomarkers and with appropriate clinical context 
were considered to have non-STEMI (NSTEMI)37. In cases of NSTEMI, an early invasive treatment strategy was 
defined as PCI within 24 h after  admission37. A successful PCI was defined as a residual stenosis of < 30% and 
more than grade 3 flow in Thrombolysis In Myocardial Infarction flow for the infarct-related artery (IRA) after 
the procedure. The primary outcome of this study was the occurrence of POCOs, defined as all-cause death, 
Re-MI, or any coronary repeat  revascularization38. The secondary outcome was definite or probable ST dur-
ing the 2-year follow-up period. All-cause death was classified as CD or non-CD. Any repeat revascularization 
comprised target lesion revascularization, target vessel revascularization, and non-TVR. Re-MI, TLR, TVR, and 
non-TVR definitions have already been published  previously39,40. The cumulative incidence of ST was defined 
by the current  consensus41.
Statistical analyses. For continuous variables, differences between the two groups were evaluated with 
the unpaired t-test. Additionally, differences among the three glycemic groups were evaluated using analysis of 
variance or the Jonckheere–Terpstra test, whereas a post-hoc analysis of the two groups was performed using 
the Hochberg test or Dunnett T3  test14; data were expressed as mean ± standard deviation. For categorical vari-
ables, intergroup differences were analyzed using chi-squared test or Fisher’s exact test, as appropriate. Data 
were expressed as numbers and  percentages14. The Kaplan–Meier method was used to estimate various clinical 
outcomes, and the log-rank test was used to compare intergroup differences (Fig. 1 and Supplementary infor-
mation). Variables with a p value of < 0.00114 or < 0.0542 in the univariate analysis and conventional risk factors 
of poor outcomes in the AMI population were considered potential confounding factors and were entered into 
the multivariate analysis. These included variables shown in Tables 2 and 3. For all analyses, two-sided values of 
p < 0.05 were considered statistically significant. All statistical analyses were performed using the SPSS software 
version 20 (IBM; Armonk, NY, USA)14.
Data availability
Data is contained with the article or supplementary information.
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